Anavex Life Sciences Corp. (AVXL) financial statements (2021 and earlier)

Company profile

Business Address 51 W 52ND STREET,
NEW YORK, NY 10019-6163
State of Incorp. NV
Fiscal Year End September 30
SIC 8731 - Commercial Physical and Biological Research (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
TTM
9/30/2020
9/30/2019
9/30/2018
9/30/2017
9/30/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments47292223279
Cash and cash equivalents47292223279
Receivables753   
Prepaid expense00 100
Other undisclosed current assets  1000
Total current assets:54352524289
Noncurrent Assets
Deposits noncurrent assets   000
Total noncurrent assets:   000
TOTAL ASSETS:54352524289
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:875443
Accounts payable444   
Accrued liabilities432   
Other undisclosed accounts payable and accrued liabilities   443
Other undisclosed current liabilities     0
Total current liabilities:875443
Noncurrent Liabilities
Total liabilities:875443
Stockholders' equity
Stockholders' equity attributable to parent46272020246
Common stock000000
Additional paid in capital21418715412911684
Accumulated deficit(168)(160)(133)(109)(91)(78)
Total stockholders' equity:46272020246
TOTAL LIABILITIES AND EQUITY:54352524289

Income statement (P&L) ($ in millions)

12/31/2020
TTM
9/30/2020
9/30/2019
9/30/2018
9/30/2017
9/30/2016
Operating expenses(33)(31)(29)(19)(16)(16)
Operating loss:(33)(31)(29)(19)(16)(16)
Nonoperating income553221
Interest and debt expense  0(0) 0
Other undisclosed loss from continuing operations before equity method investments, income taxes  (0)   
Loss from continuing operations before equity method investments, income taxes:(27)(26)(26)(17)(13)(15)
Other undisclosed income (loss) from continuing operations before income taxes   0 (0)
Loss from continuing operations before income taxes:(27)(26)(26)(17)(13)(15)
Income tax expense(0)(0)(0)(0)(0)(0)
Net loss available to common stockholders, diluted:(28)(26)(26)(17)(13)(15)

Comprehensive Income ($ in millions)

12/31/2020
TTM
9/30/2020
9/30/2019
9/30/2018
9/30/2017
9/30/2016
Net loss:(28)(26)(26)(17)(13)(15)
Comprehensive loss, net of tax, attributable to parent:(28)(26)(26)(17)(13)(15)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: